More states are telling HMOs and other health insurers to pick up the tab for pharmaceuticals and other forms of obesity treatment.
As the evidence grows regarding the role that obesity plays in many illnesses, more states are telling HMOs and other health insurers to pick up the tab for pharmaceuticals and other forms of obesity treatment.
According to StateLine,⢠Newtown, PA-based Scott-Levin's tracking system for government legislation and regulation, recent laws have taken effect in:
•Â Georgia, where the governor signed the Morbid Obesity Anti-Discrimination Act, which requires insurers to provide major medical benefits for treatment of morbid obesity.
•Â Indiana, where the governor signed a bill to require health insurers and HMOs to provide coverage for morbid obesity.
•Â Virginia, where the governor signed a bill to require coverage of gastric bypass surgery and "other recognized methods."
According to Scott-Levin, these measures represent just the beginning of this trend. In all, 26 states have recently proposed legislation addressing obesity-related issues.
The legislation is diverse. Some bills would establish commissions to study obesity and its health consequences. Others would regulate existing prescription and over-the-counter therapies for weight loss.
Underlying all this activity is the goal of state health policy-makers to better understand the true cost of obesity. PR
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.